As of March 9, 2021, there were pre-purchase agreements for over three billion doses of AstraZeneca/Oxford's vaccine. This vaccine is by far the most sought after COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines might need ultra cold storage. Although still in phase III of clinical trials and without approval, Novavax's vaccine is the one with the second highest number of orders worldwide.

Global COVID-19 vaccine contracts At the same time, India had managed to secure around 2.2 billion COVID-19 vaccines doses, followed by the European Union which had signed pre-purchase agreements to secure nearly 1.84 billion doses of COVID-19 vaccines, while the United States already secured around 1.21 billion doses. AstraZeneca/Oxford's vaccine accounted for one billion doses of all vaccines secured by India, while also accounting for 300 million doses of all vaccines secured by the EU and the U.S., respectively.

Forecasted sales of COVID-19 vaccines As of November 2021, Comirnaty by BioNTech/Pfizer was the leading COVID-19 vaccine by forecasted sales revenue. It was expected to make around 36 billion U.S. dollars in sales revenue in 2021, followed by 29 billion dollars in 2022. Meanwhile, Spikevax by Moderna was projected to make 18 billion and 22 billion U.S. dollars in 2021 and 2022, respectively. Vaxzevria by AstraZeneca was forecasted to make 1.7 billion U.S. dollars in sales, followed by an additional 1.9 billion dollars by 2022. In contrast to most other biopharmaceutical companies, AstraZeneca had announced to sell its vaccine at almost net cost price.

As of May 2021, U.S. investor Blackrock Inc owned more than seven percent of total shares of pharmaceutical companies AstraZeneca, Pfizer, Novavax, and Johnson & Johnson, respectively. The statistic illustrates major shareholdings iat select pharmaceutical companies which are involved in the development and production of COVID-19 vaccines as of May 2021, by investor.

As of June 3, 2022, there were 1,521 drugs and vaccines in development targeting the coronavirus disease (COVID-19). American biotech company Moderna was the second ranked company worldwide with 12 drugs/vaccines in development targeting COVID-19.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in va

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Moderna Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

This document provides guidance on establishment licensing, product quality and lot release to bring a COVID-19 vaccine to market in Canada.

GlaxoSmithKline generated approximately 9.3 billion U.S. dollars from vaccine sales in 2021, making it the sixth largest vaccine company in the world based on revenue. Before the pandemic and the appearance of COVID-19 vaccines, the British pharmaceutical giant used to be the global leader in vaccines.

Analyzing vaccine sales of leading companies GlaxoSmithKline reported an annual revenue of 34.1 billion British pounds in 2021 – vaccine sales accounted for around 20 percent of that figure. Year-on-year sales of Shingrix, the company’s shingles vaccine, more than doubled to almost two billion British pounds in 2020. The leading vaccine of Merck & Co. is Gardasil/Gardasil 9, which can help in the prevention of certain cancers. The vaccine is one of Merck’s top-selling products and accounted for more than half of the company’s total vaccine sales. Pfizer generated vaccine sales of nearly 43 billion U.S. dollars in 2021, of course heavily boosted by its COVID-19 vaccine sales. The pneumococcal vaccine Prevnar 13/Prevenar 13 was the company’s second product based on revenue during that year.

The race for a coronavirus vaccine Until recently, and despite growth in the global vaccine market, there were only four big pharma companies with substantial vaccine operations. However, the COVID-19 pandemic has highlighted the critical importance of vaccine research and development. Aided by government funding and partnerships, several smaller companies were among the first to enter the race to find vaccines and treatments for the disease. Biotech company Moderna, by applying its pioneering mRNA research to the problem, was among the first to bring a safe and effective COVID-19 vaccine to the broader market.

Moderna records a larger-than-expected quarterly loss as demand for COVID-19 vaccines decreases, prompting a reduction in manufacturing and impacting financial performance.

Snapshot img

Vaccine Research Market Size 2024-2028

The vaccine research market size is forecast to increase by USD 21.4 billion at a CAGR of 10.84% between 2023 and 2028. The market is witnessing substantial growth due to the persistently high prevalence of infectious diseases and the requirement for innovative vaccines to address chronic infections. Additionally, the advancement of adjuvants and vaccine delivery systems is significantly contributing to market expansion. This growth is driven by the increasing demand for efficient, accessible, and high-standard solutions. Companies in this sector are adapting their strategies to align with these trends, focusing on sustainability and operational efficiency to remain competitive. The market's future direction is influenced by these key drivers, ensuring its continued growth and evolution. As the industry progresses, the demand for advanced solutions continues to expand its scope.

What will be the size of the Vaccine Research Market during the forecast period?

Request Free Vaccine Research Market Sample

Vaccine Research Market Segmentation

The Vaccine Research market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

End-user

  Public
  Private


Age Group

  Pediatric
  Adult


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

Which is the largest segment driving market growth?

The public segment is estimated to witness significant growth during the forecast period.

Government entities, including the US National Institute of Allergy and Infectious Diseases (NIAID) and the US National Institutes of Health (NIH), play a significant role in vaccine research. In response to the COVID-19 pandemic, governments worldwide have made substantial investments in vaccine development, from basic science and pre-clinical stages through clinical trials. These efforts led to the creation of several effective COVID-19 vaccines. Governments have been instrumental in funding and supporting each phase of the vaccine development process. Immunization programs focus on various diseases, such as pneumococcal disease, measles, mumps, mono, and varicella, diphtheria, tetanus, HPV, MMR, rotavirus, influenza, hepatitis, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever, and polio.

Vaccines come in various forms, including injectable, oral, and nasal, and are produced by vaccine manufacturers, genomic research centers, academic institutions, and private laboratories. They are used in hospital settings, clinics, and pharmacies. Vaccines protect against microorganisms, toxins, and surface proteins, enhancing the immune system's response to pathogens. Vaccine research continues to address physiological disorders, allergies, cancer, and infectious diseases, such as hypertension, dyslipidemia, Alzheimer's, inflammatory diseases, and self-antigens. Vaccines are available as combination vaccines, monovaccines, subunit, recombinant, polysaccharide, live-attenuated vaccines, inactivated vaccines, and DNA vaccines. Vaccines are crucial components of preventive healthcare and public health initiatives, reducing morbidity and mortality.

Get a glance at the market share of various regions. Download the PDF Sample

The Public segment was valued at USD 12.10 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 44% to the growth of the global Vaccine Research market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The market in North America is significantly driven by the high prevalence of both infectious and non-infectious diseases. In the US, influenza, hepatitis A, hepatitis B, HIV, measles, malaria, tuberculosis, and cancer are among the most common health concerns. The prevalence of these diseases continues to increase, particularly in developed countries. For instance, influenza cases peak annually in the US during November to February. Although vaccines have led to a decline in diseases like mumps, measles, and rubella (MMR), they have not been eradicated completely. Vaccine research focuses on various types, including conjugate, recombinant, live attenuated, toxoid, and inactivated vaccines.

These vaccines target various diseases, such as meningitis, pneumonia, and polio. Stakeholders In the market include government immunization programs, preventive healthcare providers, vaccine manufacturers, genomic research centers, academic institutions, private laboratori

As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by manufacturer.

This document provides guidance to vaccine manufacturers seeking authorization for their vaccine that targets the SARS-CoV-2 virus. This guidance applies to applications under the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

As of 2022, the BioNTech vaccine against the coronavirus (COVID-19) was administered the most in Germany. Figures were significantly higher for BioNTech vaccinations, compared to the other vaccines approved for use in the EU – Moderna, AstraZeneca and Janssen. BioNTech is a German biotechnological company, which developed a vaccine against COVID-19 in cooperation with U.S. pharmaceutical giant Pfizer.

New vaccines BioNTech and Moderna are mRNA vaccines, AstraZeneca is not, but all three have one thing in common – they have to be administered in two doses over a period of several weeks to provide protection against the virus. The Janssen vaccine, also referred to as Johnson & Johnson, referring to its manufacturer, requires one dose. Both BioNTech and Moderna vaccines have already been administered as booster shots while another coronavirus wave engulfs Germany. After initial shortages in deliveries at the beginning of Germany’s vaccination campaign at the end of December 2020, production has ramped up, also within the country, and the German government repeatedly assures the population that there are enough vaccines for first, second and booster shots.

The next wave Thus far there is no national vaccination mandate in Germany, though heated debate among political parties regarding the issue continues, particularly in the wake of rising coronavirus cases in the winter of 2021 and the emergence of the Omicron variant. While all the currently greenlighted vaccines against COVID-19 are not said to make the recipient immune to the virus, they are widely hailed as helping reduce the risk of a difficult illness or the possibility of a hospital stay.

COVID-19 RNA Vaccine Market Outlook

The global COVID-19 RNA Vaccine market size was valued at approximately USD 25 billion in 2023, and it is projected to reach USD 80 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 14% during the forecast period. The significant growth factor driving this market is the unprecedented urgency and global demand for effective immunization solutions to combat the COVID-19 pandemic. The rapid development, approval, and distribution of RNA vaccines such as mRNA-1273 and BNT162b2 have revolutionized the vaccine industry, providing a novel mechanism that utilizes messenger RNA to instruct cells to produce viral proteins, thereby triggering an immune response.

The primary growth factor for the COVID-19 RNA vaccine market is the efficacy and speed of RNA vaccine development. Traditional vaccine development can take years, whereas RNA vaccines can be developed and scaled up quickly due to their synthetic nature and the simplicity of their manufacturing processes. This rapid development capability has been crucial in addressing the urgent need for COVID-19 vaccines. Additionally, RNA vaccines have exhibited high efficacy rates in clinical trials, further bolstering public confidence and demand. Innovations in RNA technology are also paving the way for improvements in storage and distribution, making these vaccines more accessible globally.

Another significant growth driver is the ongoing threat of new COVID-19 variants. As the virus mutates, the need for adaptable and quickly producible vaccines becomes more pressing. RNA vaccines offer a flexible platform that can be rapidly modified to target new viral strains. This adaptability ensures continued relevance and demand for RNA vaccines in the long term, as booster shots and updated vaccines become necessary to maintain immunity against evolving virus strains. Furthermore, global vaccination campaigns and government initiatives to secure vaccine supplies are playing a pivotal role in market growth.

The scalability of RNA vaccine production is a key factor contributing to market growth. Unlike traditional vaccines that require cell cultures or animal products, RNA vaccines can be synthesized in large quantities using relatively simple and scalable biochemical processes. This ease of production not only accelerates the manufacturing timeline but also allows for cost-effective mass production. The increased production capacity has enabled manufacturers to meet the global demand more efficiently, ensuring widespread distribution and administration of vaccines.

The emergence of mRNA Vaccines & Therapeutics has been a pivotal development in the fight against COVID-19. These vaccines, which utilize messenger RNA to instruct cells to produce viral proteins, have not only proven effective against the original strain of the virus but also offer a flexible platform for rapid adaptation to new variants. This adaptability is crucial as the virus continues to evolve, presenting new challenges in maintaining public health. The success of mRNA vaccines has sparked a broader interest in their potential applications beyond infectious diseases, exploring possibilities in cancer treatment and other therapeutic areas. This innovation marks a significant shift in vaccine technology, promising a new era of medical advancements.

The regional outlook for the COVID-19 RNA vaccine market indicates robust growth across various geographies. North America, particularly the United States, has been a leading region in terms of vaccine development and distribution, supported by substantial government funding and advanced healthcare infrastructure. Europe follows closely, with significant contributions from countries like Germany and the UK. The Asia Pacific region is also witnessing remarkable growth, driven by initiatives in countries such as China and India to ramp up vaccine production and distribution. Latin America and the Middle East & Africa are gradually increasing their market shares through international collaborations and local manufacturing efforts.

Vaccine Type Analysis

The COVID-19 RNA vaccine market is segmented by vaccine type, with major categories including mRNA-1273, BNT162b2, CVnCoV, ARCoV, and others. mRNA-1273, developed by Moderna, has been a frontrunner in the race to vaccinate the global population. Its high efficacy rate, coupled with robust production capabilities, has made it a significant player in the market. Unlike traditional vaccines, mRNA-12

The size of the Vaccine Contract Manufacturing Industry market was valued at USD 3.51 Million in 2023 and is projected to reach USD 7.37 Million by 2032, with an expected CAGR of 11.18% during the forecast period. Vaccine contract manufacturing is one of those specialized sectors that are manufacturing vaccines on behalf of other pharmaceutical companies. Several reasons push many firms into sourcing production at contract manufacturers: lower costs, increased capacity, and exploiting highly specialized expertise. In global healthcare systems, vaccine contract manufacturers play a highly significant role, especially in ensuring delivery in a timely and efficient manner in pandemic circumstances and more general public health emergencies. The process is very complex for vaccine contract manufacturing, ranging from production and culture of viral or bacterial antigens to purification, formulation, and filling into vials or syringes. The contract manufacturers must have highly set standards of quality and must meet all requirements given by the regulatory systems they use for manufacturing vaccines. The industry is very regulated since there are strict guidelines that ensure quality control and disinfection, which takes place through regular inspection. Vaccines are at the forefront in the prevention of infectious disease and in the protection of public health. They have undoubtedly been key in decreasing the cases of several diseases, including polio, measles, and smallpox. However, vaccine production does not take a lot of rocket science to perform. It is one of those tasks that require specialized facilities and equipment, as well as specialized expertise. Contract manufacturing has opened up the opportunity for pharmaceutical companies to focus on research and development and let the manufacturing process be left to experienced and reliable partners. Vaccine contract manufacturing has emerged as a critical practice in the last decade. The recent COVID-19 pandemic had leveraged the adoption of vaccine contract manufacturing. This was a race for the vaccines based on the development of COVID-19, and massive global effort included large pharmaceutical companies along with contract manufacturers who worked together towards addressing unprecedented levels of demand. Scaling up the manufacturing in the industry played a key role in curbing the spread of this virus and saving thousands of lives. Vaccine contract manufacturing is crucial not only in the management of pandemics but also in creating a solid safeguard for long-term availability of vaccines for a number of diseases. It helps pharmaceutical companies avoid reliance on a single manufacturing site that may be subject to interruptions, therefore giving less chance for break in supply chains. In addition, the factor is a critical component of vaccines supplied in developing countries where access to basic healthcare services can be really limited. Recent developments include: August 2022: Moderna inked an agreement with the Canadian government to construct a messenger RNA vaccine manufacturing factory in an undetermined location in Canada. According to the biotech firm, the partnership will give Canadians access to mRNA vaccines made in Canada against respiratory viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus., June 2022: Merck and Agilent Technologies collaborated with each other to advance process analytical technologies for downstream processing and overcome the gaps within downstream processing.. Key drivers for this market are: Advancements in Technology and Cost Benefits in Infrastructure and Operational Benefits, Increase in Initiatives Favoring Vaccinations; Favorable Patient Demographics and Growing Vaccinations of Newborns and Children. Potential restraints include: Rising High Costs of Vaccines, Lack of Storage Infrastructure and Limitations Associated with Supply Chain. Notable trends are: The Inactivated Vaccines Segment is Expected to Hold a Significant Share in the Vaccine Contract Manufacturing Market over the Forecast Period.

The Global Glass Bottles and Vials for Vaccines and Pharmaceutical market size was USD 18.27 Billion in 2022 and it is forecasted to reach USD 37.6 billion by 2030. Glass Bottles and Vials for Vaccines and the Pharmaceutical Industry's Compound Annual Growth Rate will be 9.6% from 2023 to 2030. The Driving Factor of the Glass Bottles and Vials for Vaccines and Pharmaceutical Market

Development of new glass types will drive the market

The major factor driving the Glass Bottles and Vials for Vaccines and Pharmaceutical market is the adoption of the new glass types. The newly developed glass former is used in the making of these glasses to eliminate the need of boron. The newly developed glass does not possess boron, resulting in chemically durable and uniform glass chemistry. However, Permanent engraving is being used by glass container producers to reduce years of manufacturing forgery, which is expected to increase demand. Additionally, the growth of the pharmaceutical industry over the globe drives the market.

Restraining Factor for Glass Bottles and Vials for Vaccines and Pharmaceutical Market

Rising adoption of the alternative packaging materials to hamper the growth of the market

The glass packaging is being continuously replaced by plastic in the pharmaceutical industry. Plastics have different characteristics such as cost-effectiveness, flexibility, impact resistance, easy molding, and other protective properties. The bottles made up from plastics are low cost, lightweight, and easy to transport in comparison with the glass bottles. The use of plastics for pharmaceutical packaging decreases the chances of accidental breakage owing to the high impact resistance of plastic. However, the high flexibility of plastics decreases the need for tertiary packaging of the pharmaceutical product, reducing the manufacturing and transportation cost.

Impact of the COVID-19 pandemic on the Glass Bottles and Vials for Vaccines and Pharmaceutical Market

COVID-19 had a positive impact on the Glass Bottles and Vials for Vaccines and Pharmaceutical market. This is attributed to the growing demand for vials for COVID vaccines. Pharmaceutical companies were excused from the restrictions of lockdowns due to their activities being essential for the community. This industry was operating to manufacture healthcare products and support them. What are glass bottles and vials for vaccines?

The Glass Bottles and Vials are small glass or plastic containers that store medication in liquids, powders, and capsules. The major types of glass packaging are vials, bottles, ampoules, syringes, cartridges and other products. The demand for glass bottles and vials has increased because of the end users using glass vials more often than conventional vials. Since they make recycling simple, they are also eco-friendly. Glass bottles and vials allow producers to lower production costs while providing consumers with items of higher quality. North America is going to dominate the market.

Pairwise Wilcoxon signed-rank comparisons with German COVID-19 vaccines for significant Friedman test.

Market Overview:

The United States vaccines market size is projected to exhibit a growth rate (CAGR) of 5.91% during 2024-2032. The regulatory support and approval processes, the emerging infectious diseases, the rise of telehealth and remote healthcare services, the favorable healthcare policies, and the international collaborations and partnerships are some of the factors propelling the market.

Vaccines are biological substances designed to stimulate the immune system to recognize and fight specific pathogens, such as viruses or bacteria. They play a crucial role in preventing infectious diseases and promoting public health. Vaccines are typically composed of weakened or inactivated forms of the targeted microorganism or specific components, such as proteins or genetic material. When administered, vaccines prompt the immune system to produce an immune response, including the production of antibodies and the development of immune memory. This immune memory allows the body to recognize and rapidly respond to the actual pathogen if encountered in the future, providing protection against infection and often preventing the onset of diseases. Vaccination programs have been instrumental in controlling and eradicating infectious diseases globally. Common vaccines include those for measles, mumps, rubella, polio, influenza, hepatitis, and more. In addition to individual protection, vaccines contribute to herd immunity, reducing the overall spread of infectious agents within communities. Continuous research and advancements in vaccine technology, such as mRNA vaccines, have expanded the scope and efficacy of vaccination efforts. Vaccines have been pivotal in controlling pandemics, as evidenced by their role in combating diseases like smallpox and, more recently, in the global response to the COVID-19 pandemic. They represent a powerful tool in public health, preventing illness, reducing the burden on healthcare systems, and saving countless lives by effectively bolstering the body's immune defenses against a wide array of infectious agents.

United States Vaccines Market Trends:

The market in the United States is majorly driven by the advancements in vaccine development. In line with this, the COVID-19 pandemic has accelerated vaccine research, production, and distribution efforts. The urgency to address the global health crisis has led to increased investments, collaborations, and government support for vaccine development, contributing significantly to market growth. Furthermore, the rising awareness of the importance of vaccination in preventing infectious diseases has driven demand. Routine vaccinations for diseases like influenza, measles, mumps, rubella, and hepatitis have gained prominence as individuals and healthcare providers recognize the value of immunization in maintaining public health. Government initiatives and public health programs play a pivotal role in driving the vaccine market. Programs such as the Vaccines for Children (VFC) program, which provides vaccines to eligible children, and the Adult Immunization Initiative contribute to increased vaccine accessibility and utilization. Additionally, the emergence of innovative vaccine technologies has expanded the market. mRNA vaccine platforms, as demonstrated by the success of COVID-19 vaccines, showcase the potential for rapid development and effectiveness against a variety of pathogens. This has spurred interest and investment in novel vaccine approaches, driving market growth. The aging population in the United States is a significant factor influencing the vaccine market. As individuals age, there is a higher susceptibility to certain diseases, necessitating vaccinations to prevent complications. This demographic shift contributes to the demand for vaccines targeting conditions prevalent in older adults, such as shingles and pneumococcal diseases. Pharmaceutical companies and biotech firms are increasingly focusing on vaccine research and development. Partnerships between industry players and research institutions, along with advancements in vaccine manufacturing technologies, drive innovation and contribute to the growth of the vaccine market. Besides, the growing importance of travel vaccines, as people increasingly engage in international travel, adds to market expansion. Vaccines for diseases prevalent in different regions become essential for travelers, promoting a global market for travel-related immunizations.

United States Vaccines Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.

Technology Insights:

https://www.imarcgroup.com/CKEditor/4df2be45-fb2f-4a09-890a-76b18e7708deother-regions1.webp" style="height:450px; width:800px" />

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others
  

The report has provided a detailed breakup and analysis of the market based on the technology. This includes conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and others.

Patient Type Insights:

• Pediatric
• Adult
  

A detailed breakup and analysis of the market based on patient type have also been provided in the report. This includes pediatric and adult.

Indication Insights:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others
    

The report has provided a detailed breakup and analysis of the market based on the indication. This includes bacterial diseases (meningococcal disease, pneumococcal disease, diphtheria/tetanus/pertussis (DPT), tuberculosis, haemophilus influenzae (HIB), typhoid, and others) and viral diseases (hepatitis, influenza, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue, and others).

Route of Administration Insights:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others
  

A detailed breakup and analysis of the market based on route of administrations have also been provided in the report. This includes intramuscular and subcutaneous administration, oral administration, and others.

Product Type Insights:

• Multivalent Vaccine
• Monovalent Vaccine
  

<p

Novavax sells its Czech manufacturing facility to Novo Nordisk for $200 million, focusing on strengthening its vaccine pipeline and operational efficiency.

Covid-19 Vaccine Market size was valued at USD 7.64 Billion in 2024 and is projected to reach USD 12.64 Billion by 2031, growing at a CAGR of 7.16% during the forecasted period 2024 to 2031.

The COVID-19 vaccine market is driven by the persistent threat of emerging variants, which necessitates ongoing vaccine development and booster campaigns to ensure population immunity. Government funding and international collaborations, such as those facilitated by COVAX, play a pivotal role in accelerating research, production, and equitable distribution. Advances in mRNA and other vaccine technologies have further spurred innovation in the sector. Additionally, increasing public awareness of vaccination benefits and the integration of vaccines into routine immunization programs contribute to sustained demand. The expansion of cold-chain logistics and regional vaccine manufacturing capabilities has also enhanced market accessibility, particularly in low- and middle-income countries.